<GlossaryTerm id="CDR0000749332"><TermName>Sylatron</TermName><TermPronunciation>(SY-luh-tron)</TermPronunciation><TermDefinition><DefinitionText>A drug that is no longer available in the United States that contains the active ingredient peginterferon alfa-2b and was used to prevent melanoma from coming back after it has been removed by surgery. Sylatron is a type of cytokine and a type of immunomodulating agent.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000752611" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Sylatron&quot;" language="en" id="_3"/><MediaLink ref="CDR0000752610" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Sylatron&quot;" language="es" id="_4"/><SpanishTermName>Sylatron</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento, no disponible en los Estados Unidos, que contiene el principio activo peginterferón α-2b y se usaba para prevenir que el melanoma reaparezca después de que se extirpa mediante cirugía.   Sylatron es un tipo de citocina y de inmunomodulador.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2013-05-09</DateFirstPublished><DateLastModified>2023-04-06</DateLastModified></GlossaryTerm>
